Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LALPATHLAB.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LALPATHLAB.BO and 80,000+ other tickers.
See exactly how LALPATHLAB.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LALPATHLAB.BO and 80,000+ other tickers.
Dr. Lal PathLabs Limited runs diagnostic laboratories, performing an extensive range of pathological analyses across India and internationally. The company's comprehensive offerings span various scientific fields such as biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, and cytology, in addition to other specialized pathological and radiological examinations. Furthermore, it provides educational training programs. Founded in 1949, the firm is based in Gurugram, India.
No recent news available.